Tag: ROTH

Sticking with SPY Puts

Solid Hits on the SPY

We try to formulate new options ideas for a given session as often as we can without forcing the issue, and on most days we produce at least one. Yesterday, we designated our sole set of new contracts to watch as the SPY Weekly $250-248 Puts, and thanks to a painful day for the markets, we were afforded the chance to score some pretty nice intraday gains.

Two out of three of those strike points translated into instant double-bag opportunities, with the third falling just 1% short of that mark, providing the following moves on the day: 

SPY Weekly $250-248 Puts
$250: 4.39-8.73 (+99%)
$249: 4.00-8.10 (+103%)
$248: 3.65-7.50 (+105%)
______

Fresh Ideas:
SPY Weekly $244-242 Puts
WBA Weekly $44-45 Calls
KMX Weekly $50-55 Calls


CytoDyn, Inc. CYDY

We began tracking CYDY on Tuesday morning, and in addition to making a nominal move on the chart, the company has also put out some coronavirus related press in the couple days. One of the company’s investigational drugs which is about to enter Phase 2b/3 trials, has demonstrated a promising level of  efficacy among severe COVID-19 patients.

The stock itself has run from 2.65-3.09 in the past couple of sessions, which marks a move of just 17% but we’re going to be interested to continue tracking its performance in light of the company’s announcements.

VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the three-day effect of leronlimab in eight severely ill COVID-19 patients demonstrated a significant improvement in several important immunologic bio-markers.  Patient test data reveals improvement in cytokines, IL-6, and a trend toward the normalization of the CD4/CD8 ratio. (>>View Full PR)


Extended Watchlist:
GRYO, PNAT, ROTH, SOLI, CTYX, IPIX

Blue Horseshoe Stocks: BIEL Recap, VAPE & More

BioElectronics Corp. BIEL

BIEL was a big winner among the stocks that we were monitoring following yesterday morning’s report. The stock traded in a range from .001-.0025, registering as an excellent 150% intraday move. It occurred on the highest daily volume recorded in more than 8 months, to the tune of nearly 11X its monthly average.

After seeing that kind of momentum building up, we’re curious as to how the action will unfold. If BIEL can maintain support above previous resistance at .0016 on any pullbacks, we’ll continue to reserve a spot for it on our watchlist.

Vape Holdings, Inc. VAPE

VAPE has turned out to be an excellent bottom-bounce call for us. After re-highlighting it in yesterday’s report we saw a nice 31% intraday pop from .052-.068, which also registered a new high since we’ve been following the stock.

We first brought this one up in our reports just over a week ago when we put it on bottom-watch, and last Tuesday it set a new annual low of .021. From that point on it has recorded higher highs and higher lows each day. As of yesterday’s new high, we had witnessed a one week swing of 224%

PharmaRoth Labs, Inc. ROTH

We also want to quickly point out a stock that we’ve been tracking recently which has produced a positive news announcement this morning with regard to its Type-II diabetes treatment, Sucanon(R). ROTH has been largely trading sideways since we tagged it for observation at the end of last week, but we’re going to want to keep a closer watch over the stock on the heels of this morning’s PR.

LAS VEGAS, NV–(Marketwired – Oct 13, 2015) – PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that Sucanon® has been approved for over the counter sales in Canada as a natural health product. The approval comes through Health Canada, the regulating health-care agency of Canada. >>FULL PR

Extended Watchlist:
PENC, CCTC, PLKD, EGYH, NNRX

Blue Horseshoe Stocks: UVXY Recap, Options Review & More

Options Updates

ProShares Ultra VIX Short-Term Futures (UVXY) – 

In Friday’s premarket report, we essentially served up our readers an absolute gem of an options idea on a silver platter, when we identified the high potential of some prime intraday flip opportunities.

We posited that the overall markets would see a pullback, and offered our take on a good way to leverage that eventuality for quick-strike gains in weekly UVXY contracts. The markets were indeed hammered back for most of the session, and as a result, our assumptions paid off in spades.

Our specified target range included UVXY Weekly $73-78 Calls, and every last set of contracts provided us with the chance to bank multi-bag gains. Check it out:

$73 Calls  – Daily Range: 2.17-8.10 – Max Gain: 273%
$74 Calls  – Daily Range: 1.47-7.20 – Max Gain: 390%
$75 Calls  – Daily Range: 1.17-6.40 – Max Gain: 447%
$76 Calls  – Daily Range: 1.10-4.53 – Max Gain: 312%
$77 Calls  – Daily Range: 77-4.34 – Max Gain: 464%
$78 Calls  – Daily Range: .57-3.68 – Max Gain: 545%

Updated Idea:

With another reversal appearing likely with this morning’s gap-up in the markets, we’ll want to swing our attention in the opposite direction. The SPY generally trades inversely to the UXVY, thus we’ll be monitoring SPY Weekly $195-197 Calls in the event of a continued uptrend signal.

____

Longer-Term Ideas – Update

For each of the past two Thursdays, we’ve mentioned our interest in a set of longer-term options ideas for a number of tech stocks, namely the 9/18-10/02  FB, GPRO, GMCR, AAPL, NFLX, and TSLA Calls.

With between 1.5-3.5 weeks until expiration on the contracts contained in that range, we’ve seen some nice moves already, and we want to continue to keep an eye on this whole group. With the volatile flux we’ve observed in recent market activity, further opportunities could certainly present themselves in coming sessions.


PharmaRoth Labs, Inc. ROTH

We noticed some exciting news hitting the wires this morning for ROTH, and the PPS is currently down to a relative bottom, so we’re going to tab this subpenny play for extended observation.